Pancreatic Cancer Therapeutics Market worth $9.09 billion by 2030 - Exclusive Report by 360iResearch

The Global Pancreatic Cancer Therapeutics Market to grow from USD 4.25 billion in 2022 to USD 9.09 billion by 2030, at a CAGR of 9.93%.



Pancreatic Cancer Therapeutics Market - Exclusive Report by 360iResearch

PUNE, MAHARASHTRA, INDIA , December 6, 2023 /EINPresswire.com/ -- The "Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global Pancreatic Cancer Therapeutics Market to grow from USD 4.25 billion in 2022 to USD 9.09 billion by 2030, at a CAGR of 9.93%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/pancreatic-cancer-therapeutics?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

Pancreatic cancer therapeutics encompass a variety of treatment modalities used to manage and combat pancreatic cancer, known for its aggressive nature and challenging prognosis. The therapeutic landscape for this malignancy includes surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and supportive care measures that aim to relieve symptoms and improve the quality of life for patients. The need for pancreatic cancer therapeutics is driven by the increasing prevalence of the disease, attributed to factors such as aging populations, lifestyle-related risk factors, and genetic predispositions. Additionally, supportive government policies to expand access to affordable pancreatic cancer treatment have extended the scope and reach of the therapeutic options for patients. However, the complex reimbursement landscape and the inability of clinical trials to provide beneficial and credible results pose

concerns about the accuracy and efficacy of the therapies. Moreover, there has been some significant progress in understanding the biology of the disease, resulting in the development of targeted therapeutics and personalized medicine approaches. These treatments are designed to interfere with specific pathways or mechanisms that promote the growth and spread of pancreatic cancer cells.

Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
Pancreatic neuroendocrine tumors (NETs), also called endocrine pancreatic cancer or islet cell tumors, are a type of cancer associated with the rapid and abnormal growth of endocrine cells, called islet cells, in the pancreas. Treatment for this type of cancer usually involves surgery to remove the tumor cells or the major parts of the body and tail of the pancreas. Furthermore, for tumors that cannot be removed by surgery, treatment may include a combination of chemotherapy or hormone therapy. Exocrine pancreatic cancer, or adenocarcinoma, refers to cancers that form in the tissue of the pancreas, within the ducts that carry pancreatic juices and aid digestion. However, compared to endocrine pancreatic cancers, exocrine pancreatic cancers advance rapidly.

Product: Expanding number of approvals for chemotherapy treatment options
Chemotherapy remains an essential pillar in the treatment of pancreatic cancer, involving systemic drug administration to impede cancer cell proliferation. These cytotoxic medications can be taken orally or injected, and their inability to distinguish between malignant and normal cells results in side effects. However, chemotherapy is a critical component of the therapeutic regimen, employed alongside other strategies to enhance patient outcomes. Gene therapy represents a cutting-edge technique, delivering new genetic material into patients' cells to rectify defective genes responsible for cancer growth or to introduce genes that trigger an immune response against tumor cells. Presently, gene therapy for pancreatic cancer is largely exploratory and confined to clinical research, holding the promise of more precise, individualized treatments in the future. Immunotherapy is a rapidly evolving field that leverages the body's immune defenses against cancer. Pancreatic cancer treatments, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies, are scrutinized for their ability to target cancer cells effectively. The efficacy of immunotherapy in pancreatic cancer varies. However, ongoing investigations are assessing its potential, especially for patients with specific genetic markers. Radiation therapy, a technique employing high-energy particles to eradicate cancer cells, can serve as a solitary treatment or in combination with surgical interventions to manage pancreatic cancer. Technological advancements such as stereotactic body radiation therapy (SBRT) enhance the accuracy of radiation delivery, minimizing collateral damage to healthy tissues. Surgery is the preferred approach for early-stage pancreatic cancer, aiming to excise the tumor completely. Various surgical techniques, such as the Whipple procedure or distal pancreatectomy, are determined by the tumor's pancreatic location. The viability of surgery depends on the cancer's stage and the patient's health status, and it is typically augmented by chemotherapy and radiation to optimize results. Targeted therapy offers a more nuanced attack on cancer by pinpointing and inhibiting specific molecular abnormalities or pathways involved in tumor

progression.

End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
Clinics provide personalized care with a focus on chemotherapy and patient follow-up. However, hospitals are at the core of providing comprehensive care for pancreatic cancer patients as they provide advanced surgery procedures and post-operative care facilities. They are pivotal in conducting major surgical procedures such as Whipple procedures, which are essential for treating operable pancreatic cancer. Research and academic institutions collaborate with biopharmaceutical companies to develop and test new treatments. Furthermore, they provide a foundation for evidence-based practice and contribute to the overall understanding of disease management, which can translate into improved drugs and care strategies.

Regional Insights:
The Americas region, particularly the United States and Canada, is characterized by the presence of a robust clinical pipeline, high healthcare expenditure, and several major pharmaceutical companies. Food and Drug Administration (FDA) has approved designations such as Fast Track, Breakthrough Therapy, and Orphan Drug to several pancreatic cancer drugs, which accelerates the regulatory approval process. European nations such as Germany, France, and the United Kingdom are characterized by the presence of heightened healthcare spending, advanced healthcare facilities, and favorable reimbursement policies. The European Medicines Agency (EMA) plays a pivotal role in endorsing new therapeutic options, positively impacting market growth. Strong research collaborations between private and public entities drive innovation in cancer therapeutic research. In APAC countries such as China, Japan, India, and South Korea, there is a growing patient population and increasing awareness regarding cancer diseases, driving the need for therapeutic options. The increase in local generic drug production in countries such as India contributes to regional market dynamics.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Pancreatic Cancer Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Pancreatic Cancer Therapeutics Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also

sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/pancreatic-cancer-therapeutics?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Pancreatic Cancer Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Endocrine Pancreatic Cancer and Exocrine Pancreatic Cancer. The Exocrine Pancreatic Cancer commanded largest market share of 72.14% in 2022, followed by Endocrine Pancreatic Cancer.

Based on Product, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy. The Chemotherapy commanded largest market share of 34.33% in 2022, followed by Radiation Therapy.

Based on End-Use, market is studied across Cancer Centers/Clinics, Hospitals, and Research Institutes. The Hospitals commanded largest market share of 42.65% in 2022, followed by Research Institutes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France,

Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 43.47% in 2022, followed by Europe, Middle East & Africa.

Key Topics Covered:

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Pancreatic Cancer Therapeutics Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Pancreatic Cancer Therapeutics Market?
3. What is the competitive strategic window for opportunities in the Pancreatic Cancer Therapeutics Market?
4. What are the technology trends and regulatory frameworks in the Pancreatic Cancer Therapeutics Market?

5. What is the market share of the leading vendors in the Pancreatic Cancer Therapeutics Market?
6. What modes and strategic moves are considered suitable for entering the Pancreatic Cancer Therapeutics Market?

Read More @ https://www.360iresearch.com/library/intelligence/pancreatic-cancer-therapeutics?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+1 530-264-8485
ketan@360iresearch.com
